Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CEO Quang Pham sold 12,992 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $4.06, for a total value of $52,747.52. Following the completion of the transaction, the chief executive officer directly owned 154,339 shares of the company’s stock, valued at approximately $626,616.34. This trade represents a 7.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Cadrenal Therapeutics Stock Down 8.2%
Cadrenal Therapeutics stock opened at $3.70 on Friday. The business has a 50 day moving average price of $5.04 and a two-hundred day moving average price of $6.66. The stock has a market cap of $10.62 million, a price-to-earnings ratio of -0.66 and a beta of 1.59. Cadrenal Therapeutics, Inc. has a 12 month low of $3.70 and a 12 month high of $14.69.
Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, beating the consensus estimate of ($1.51) by $0.47. On average, analysts expect that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on CVKD
Hedge Funds Weigh In On Cadrenal Therapeutics
A number of hedge funds have recently modified their holdings of CVKD. JPMorgan Chase & Co. bought a new stake in Cadrenal Therapeutics during the 3rd quarter worth approximately $103,000. Geode Capital Management LLC grew its position in Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after acquiring an additional 1,818 shares during the last quarter. Citadel Advisors LLC bought a new stake in Cadrenal Therapeutics during the 3rd quarter worth approximately $274,000. Finally, DRW Securities LLC bought a new stake in Cadrenal Therapeutics during the 4th quarter worth approximately $171,000. 7.92% of the stock is owned by institutional investors and hedge funds.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Featured Stories
- Five stocks we like better than Cadrenal Therapeutics
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
